← All trials
NCT06207175
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 21, 2023
- Primary completion
- Nov 17, 2024
- Completion date
- Jan 25, 2026
- First posted
- Jan 16, 2024
- Last posted
- Jan 23, 2024
- Enrollment
- 1260
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Beijing Health Guard Biotechnology, IncLead sponsor
- Beijing Health Guard Biotechnology, IncOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.